Detection of antibodies in neuropathy patients by synthetic GM1 mimics

Glycobiology

Volumn 21, Issue 12, 2011, Pages 1642-1650

  Pukin, Aliaksei V ^a   Jacobs, Bart C ^b   Tio Gillen, Anne P ^b   Gilbert, Michel ^c   Endtz, Hubert P ^b   Van Belkum, Alex ^b   Visser, Gerben M ^a   Zuilhof, Han ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

antibody; diagnostics; ganglioside mimics; GM1 ganglioside; neuropathy

Indexed keywords

CHOLERA TOXIN; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COVALENT BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; GUILLAIN BARRE SYNDROME; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEUROPATHY; NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; G(M1) GANGLIOSIDE; GUILLAIN-BARRE SYNDROME; HUMANS; MOLECULAR MIMICRY; PARAPROTEINEMIAS; POLYNEUROPATHIES;

BOVINAE;

EID: 81855168321     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwr093     Document Type: Article

References (44)

1. Bock VD, Hiemstra H, van Maarseveen JH. 2006. Cu(I)-catalyzed alkyne-azide click cycloadditions from a mechanistic and synthetic perspective. Eur J Org Chem. 2006:51-68.
2. Deisenhammer F, Keir G, Pfausler B, Thompson EJ. 1996. Affinity of anti-GM1 antibodies in Guillain-Barre syndrome patients. J Neuroimmunol. 66:85-93.
3. Greenshields KN, Halstead SK, Zitman FMP, Rinaldi S, Brennan KM, O'Leary C, Chamberlain LH, Easton A, Roxburgh J, Pediani J, et al. 2009. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest. 119:595-610.
4. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, et al. 1994. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest. 104:697-708. (Pubitemid 29536355)
5. Jacobs BC, vanDoorn PA, Schmitz PIM, TioGillen AP, Herbrink P, Visser LH, Hooijkaas H, vanderMeche FGA. 1996. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol. 40:181-187.
6. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2006a. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neuroimmunol. 178:126-126.
7. Kaida K, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2006b. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 77:1043-1046. (Pubitemid 44338527)
8. Kaida KI, Kanzaki M, Morita D, Kamakura K, Motoyoshi K, Kusunoki S. 2006. Anti-ganglioside complex antibodies in Miller Fisher syndrome. Ann Neurol. 60:S38-S38.
9. Kaida K, Kanzaki M, Sada M, Hirakawa M, Motoyoshi K, Kamakura K, Kusunoki S. 2007. Anti-ganglioside complex antibodies in Miller Fisher syndrome and Guillain-Barre syndrome with ophthalmoplegia. J Peripher Nerv Syst. 12:42-43.
10. Kaida KI, Kanzaki M, Sada M, Motoyoshi K, Kamakura K, Kusunoki S. 2007. Auti-ganglioside complex antibodies in Miller Fisher syndrome and Guillain-Barre syndrome with ophthalmoplegia. Ann Neurol. 62:S62-S62.
11. Kaida K, Kusunoki S. 2008. Ganglioside complexes as target antigens in Guillain-Barre syndrome and related disorders. Future Lipidology. 3:425-434.
12. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2004. Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol. 56:567-571. (Pubitemid 39319349)
13. Kaida KI, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2005. Anti-ganglioside complex antibodies associated with severe disability and mechanical ventilation in Guillain-Barre syndrome. J Peripher Nerv Syst. 10:40-40.
14. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, Kusunoki S. 2007. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol. 182:212-218. (Pubitemid 46026709)
15. Kaji R. 2008. Diagnosis and treatment of multifocal motor neuropathy. Curr Treat Options Neurol. 10:103-107. (Pubitemid 351460255)
16. Kanzaki M, Kaida K, Ueda M, Morita D, Hirakawa M, Motoyoshi K, Kamakura K, Kusunoki S. 2008. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry. 79:1148-1152.
17. Kleinschnitz C, Reiners K. 2006. Multifocal motor neuropathy: Clinical features, pathophysiology and therapy. Klinische Neurophysiologie. 37:169-179. (Pubitemid 44638964)
18. Kornberg AJ, Pestronk A, Bieser K, Ho TW, McKhann GM, Wu HS, Jiang Z. 1994. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol. 35:234-237. (Pubitemid 24050161)
19. Kuijf ML, Godschalk PCR, Gilbert M, Endtz HP, Tio-Gillen AP, Ang CW, van Doom PA, Jacobs BC. 2007. Origin of ganglioside complex antibodies in Guillain-Barre syndrome. J Neuroimmunol. 188:69-73. (Pubitemid 47095018)
20. Kuijf ML, van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, Hooijkaas H, Hop WCJ, Jacobs BC. 2005. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci. 239:37-44. (Pubitemid 41617413)
21. Kusunoki S, Kaida KI, Ueda M. 2008. Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome: New aspects of research. Biochim Biophys Acta Gen Subj. 1780:441-444. (Pubitemid 351381251)
22. Manova R, van Beek T, Zuilhof H. 2011. Surface functionalization by strainpromoted Alkyne-Azide click reactions Angew. Chem Int Ed. 50:5428-5430.
23. Marcus DM. 1990. Measurement and clinical importance of antibodies to glycosphingolipids. Ann Neurol. 27:S53-S55. (Pubitemid 20178655)
24. Nobile-Orazio E, Cappellari A, Priori A. 2005. Multifocal motor neuropathy: Current concepts and controversies. Muscle Nerve. 31:663-680. (Pubitemid 40734675)
25. Notturno F, Caporale CM, Uncini A. 2008. Anti-ganglioside complex antibodies in Guillain-Barre syndrome. J Peripher Nerv Syst. 13:178-179.
26. Notturno F, Luciani M, Caporale CM, Ciarelli A, Uncini A. 2009. Antibodies to ganglioside complexes in Guillain-Barre syndrome: Clinical correlates, fine specificity and complement activation. Int J Immunopathol Pharmacol. 22:437-445.
27. Ogawa G, Kaida K, Kusunoki S, Ueda M, Kimura F, Kamakura K. 2009. Antibodies to ganglioside complexes consisting of asialo-GM1 and GQ1b or GT1a in Fisher and Guillain-Barre syndromes. J Neuroimmunol. 214:125-127.
28. Paterson G, Wilson G, Kennedy PG, Willison HJ. 1995. Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse V region gene usage with extensive somatic mutation. J Immunol. 155:3049-3059.
29. Pukin AV, Branderhorst HM, Sisu C, Weijers C, Gilbert M, Liskamp RMJ, Visser GM, Zuilhof H, Pieters RJ. 2007. Strong inhibition of cholera toxin by multivalent GM1 derivatives. Chembiochem. 8:1500-1503. (Pubitemid 47436905)
30. Pukin AV, Weijers C, van Lagen B, Wechselberger R, Sun B, Gilbert M, Karwaski MF, Florack DEA, Jacobs BC, Tio-Gillen AP, et al. 2008. GM3, GM2 and GM1 mimics designed for biosensing: Chemoenzymatic synthesis, target affinities and 900 MHz NMR analysis. Carbohydr Res. 343:636-650.
31. Rajabally YA. 2008. Multifocal motor neuropathy: Review of a treatable immune mediated disorder. Postgrad Med J. 84:287-292.
32. Rinaldi S, Brennan KM, Goodyear CS, O'Leary C, Schiavo G, Crocker PR, Willison HJ. 2009. Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology. 19:789-796.
33. Todeschini AR, Dos Santos JN, Handa K, Hakolmori SI. 2008. Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway. Proc Natl Acad Sci USA. 105:1925-1930. (Pubitemid 351439441)
34. Townson K, Boffey J, Nicholl D, Veitch J, Bundle D, Zhang P, Samain E, Antoine T, Bernardi A, Arosio D, et al. 2007. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology. 17:294-303. (Pubitemid 46344681)
35. Van Asseldonk JTH, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. 2005. Multifocal motor neuropathy. Lancet Neurol. 4:309-319. (Pubitemid 40545042)
36. Vanschaik IN, Bossuyt PMM, Brand A, Vermeulen M. 1995. Diagnostic-value of GM1 antibodies in motor-neuron disorders and neuropathies-a meta-analysis. Neurology. 45:1570-1577.
37. Vanschaik IN, Vermeulen M, Vandoorn PA, Brand A. 1994. Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg). J Neuroimmunol. 54:109-115. (Pubitemid 24312629)
38. Willison HJ. 2005a. Ganglioside complexes: New autoantibody targets in Guillain-Barre syndromes. Nat Clin Pract Neurol. 1:2-3.
39. Willison HJ. 2005b. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst. 10:94-112.
40. Willison HJ. 2006. Ganglioside complexes as targets for antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 77:1002-1003. (Pubitemid 44338516)
41. Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA, Illa I, Jacobs BC, Zielasek J, Hughes RAC. 1999. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol. 6:71-77. (Pubitemid 29092362)
42. Willison HJ, Yuki N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 125:2591-2625. (Pubitemid 35423511)
43. Yuki N. 2001. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis. 1:29-37. (Pubitemid 33586038)
44. Yuki N. 2005. Carbohydrate mimicry: A new paradigm of autoimmune diseases. Curr Opin Immunol. 17:577-582. (Pubitemid 41506900)